Perspectives from the 2018 ASH Annual Meeting
December 10, 2018
Share:
The 2018 Annual Meeting of the American Society of Hematology (ASH) took place in San Diego on December 1-4. As the world’s largest hematology congress, ASH highlighted extraordinary advances in cutting edge therapeutics for both blood cancers and hematologic rare diseases. Below, Clarion presents a summary of important findings and insights emerging from the meeting.
Key takeaways
- Hematologic cancers—Novel targeted therapies, combinations, and immunotherapies are poised to redefine standards of care in AML, MDS, multiple myeloma, non-Hodgkin lymphoma, and CLL
- Hematologic rare diseases—New disease-modifying targeted therapies are emerging for sickle cell disease (SCD), while the gene therapy field strives to realize its potential in SCD, hemophilia B & A, and other genetic disorders